ABSTRACT
INTRODUCTION: The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals. Pregnant HIV patients exposed to subtherapeutic doses, particularly in the last trimester of the pregnancy, have higher chances to transmit the infection to their children. Therefore, the therapeutic drug monitoring of antiretrovirals in HIV pregnant patients would be of great value. OBJECTIVES: This study aimed to develop and validate a sensitive liquid chromatograph tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of efavirenz, raltegravir, atazanavir, and ritonavir in dried blood spots (DBS) and plasma. DESIGN AND METHODS: The analytes were extracted from the DBS punch and plasma with a mixture of methanol:zinc sulfate 200 mM (50:50, v/v) and 100 % methanol, respectively. For the chromatographic separation a Shim-pack® C18, 4.6 mm × 150 mm, 5 µm column was used. Detection was performed in a 3200-QTRAP® mass spectrometer, with a run time of 6 min. RESULTS: The assay was linear in the range of 15-1,000 ng/mL for raltegravir, 50-10,000 ng/mL for both atazanavir and ritonavir, 50-5,000 ng/mL for efavirenz. Precision and accuracy at these concentrations were less than 15 % for all analytes. Raltegravir, atazanavir, and ritonavir were stable for seven days at 23 °C and 40 °C, whereas efavirenz was stable for twenty-four hours at the same conditions. CONCLUSIONS: The method was successfully applied to quantify efavirenz in DBS samples obtained from HIV-1 infected pregnant volunteers under antiretroviral therapy. The concentrations of efavirenz in DBS and plasma were comparable according to Passing-Bablok regression and Bland-Altman analysis.
Subject(s)
Alkynes , Benzoxazines , Cyclopropanes , Dried Blood Spot Testing , Drug Monitoring , HIV Infections , Tandem Mass Spectrometry , Humans , Female , Benzoxazines/blood , Benzoxazines/pharmacokinetics , Benzoxazines/therapeutic use , Cyclopropanes/blood , Pregnancy , Tandem Mass Spectrometry/methods , Drug Monitoring/methods , Dried Blood Spot Testing/methods , HIV Infections/drug therapy , HIV Infections/blood , Atazanavir Sulfate/blood , Atazanavir Sulfate/therapeutic use , Atazanavir Sulfate/pharmacokinetics , Ritonavir/blood , Ritonavir/therapeutic use , Chromatography, Liquid/methods , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/blood , Raltegravir Potassium/blood , Raltegravir Potassium/therapeutic use , Anti-HIV Agents/blood , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/pharmacokinetics , Liquid Chromatography-Mass SpectrometryABSTRACT
BACKGROUND: HIV treatment of neonates requires identifying appropriate antiretroviral dosing regimens. Our aims were to characterize raltegravir elimination kinetics in low birth weight (LBW) neonates after maternal dosing and to develop a pharmacokinetic model to predict raltegravir plasma concentrations for term and preterm neonates. METHODS: Mothers living with HIV who received raltegravir during pregnancy and their LBW neonates participated in IMPAACT P1097 study. Up to 6 serial plasma samples were collected from each infant over the first 2 postnatal weeks to characterize raltegravir elimination. Safety laboratory evaluations were obtained, and infants were monitored for 6 weeks for signs of raltegravir toxicity. An integrated maternal-neonatal pharmacokinetic model was developed to predict neonatal raltegravir plasma concentrations. RESULTS: Sixteen mothers and their 18 LBW neonates were enrolled. The median (range) raltegravir elimination half-life was 24.4 (10.1-83) hours (N = 17 neonates). No adverse events related to raltegravir in utero exposure were observed. Pharmacokinetic modeling revealed that raltegravir clearance in full-term LBW neonates was well described by allometric scaling but clearance in preterm LBW neonates was better described using slower clearance maturation kinetics. Simulations suggest receipt of the current dosing recommendations in a 34-week gestation neonate would result in plasma concentrations up to 2.5-fold higher than those observed in full-term LBW infants. CONCLUSIONS: Modeling suggests that prematurity reduces raltegravir clearance and a modified raltegravir dosing regimen will be necessary to avoid elevated plasma raltegravir concentrations.
Subject(s)
Anti-HIV Agents/pharmacokinetics , Infant, Low Birth Weight/metabolism , Infant, Newborn , Infant, Premature/metabolism , Raltegravir Potassium/pharmacokinetics , Anti-HIV Agents/blood , Female , Glucuronosyltransferase/genetics , Half-Life , Humans , Infant, Low Birth Weight/blood , Infant, Newborn/blood , Infant, Newborn/metabolism , Infant, Premature/blood , Male , Polymorphism, Single Nucleotide/genetics , Raltegravir Potassium/bloodABSTRACT
STUDY OBJECTIVE: The ANRS163-ETRAL study showed that etravirine 200 mg/raltegravir 400 mg twice-daily dual therapy was highly effective in the treatment of human immunodeficiency virus (HIV)-infected patients older than 45 years, with virologic and therapeutic success rates at week 48 of 99.4% and 94.5%, respectively. The objective of this study was to determine whether a clinically significant pharmacokinetic interaction between etravirine and raltegravir exists by assessing steady-state total and unbound etravirine, raltegravir, and inactive raltegravir-glucuronide concentrations 12 hours after last intake (C12h ) in blood plasma (BP) and seminal plasma (SP). DESIGN: Pharmacokinetic analysis of data from the ANRS163-ETRAL study. PATIENTS: One hundred forty-six HIV-1-infected patients (of the 165 patients included in the ANRS-163 ETRAL study) who were receiving etravirine 200 mg and raltegravir 400 mg twice daily. MEASUREMENTS AND MAIN RESULTS: Blood was collected from all 146 patients at weeks 2-4, 12, 24, and 48, and semen was collected from 21 patients at week 48. The extent of BP and SP protein binding was determined by using ultrafiltration assay. Total and unbound etravirine, raltegravir, and raltegravir-glucuronide C12h were determined by ultra high performance liquid chromatography coupled with tandem mass spectrometry and interpreted by using the in vitro calculated protein-bound 95% inhibitory concentration (PBIC95 ) for wild-type (WT) HIV: etravirine (116 ng/ml) and raltegravir (15 ng/ml). Median (interquartile range [IQR]) total BP etravirine C12h (536 ng/ml [376-719]) and raltegravir (278 ng/ml [97-690]) were adequate in 99% and 96% of patients, respectively. Median (IQR) SP:BP C12h ratio and BP unbound fraction were etravirine 0.3 (0.2-0.5) and < 1%, respectively, raltegravir 1.8 (1.3-3.3) and 12%, respectively, and raltegravir-glucuronide 12.0 (6.5-17.7) and > 99%, respectively. The BP raltegravir metabolic ratio (raltegravir glucuronide:raltegravir ratio) was 1.7, suggesting only weak induction of raltegravir glucuronidation by etravirine. Only three patients had etravirine and raltegravir C12h < PBIC95 simultaneously. CONCLUSION: No clinically significant pharmacokinetic interaction between etravirine and raltegravir was detected. Total etravirine and raltegravir BP concentrations were adequate in most patients, favoring virologic efficacy and confirming good treatment adherence (> 95%), despite twice-daily administration. The long half-life of etravirine and higher unbound fraction SP of raltegravir (57%) ensured adequate concentrations of dual therapy in genital compartments. Our results indicate that etravirine and raltegravir have good, complementary pharmacokinetic profiles, suggesting that they could be used in a dual-treatment strategy.
Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , HIV Infections/drug therapy , Pyridazines/administration & dosage , Pyridazines/pharmacokinetics , Raltegravir Potassium/administration & dosage , Raltegravir Potassium/pharmacokinetics , Semen/drug effects , Anti-HIV Agents/blood , Anti-HIV Agents/therapeutic use , Drug Interactions , Drug Therapy, Combination , Female , HIV Infections/blood , HIV-1/drug effects , Humans , Male , Middle Aged , Nitriles , Protein Binding , Pyridazines/blood , Pyridazines/therapeutic use , Pyrimidines , Raltegravir Potassium/blood , Raltegravir Potassium/therapeutic use , Semen/metabolismABSTRACT
Volumetric absorptive microsampling (VAMS), a new microsampling technique, was evaluated for its potential in supporting regulated bioanalysis. Our initial assessment with MK-0518 (raltegravir) using a direct extraction method resulted in 45-52% extraction recovery, significant hematocrit (Ht) related bias, and more importantly, unacceptable stability (>15% bias from nominal concentration) after 7-day storage. Our investigation suggested that the observed biases were not due to VAMS absorption, sampling techniques, lot-to-lot variability, matrix effect, and/or chemical stability of the compound, but rather the low extraction recovery. An effort to improve assay recovery led to a modified liquid-liquid extraction (LLE) method that demonstrated more consistent performance, minimal Ht impact (Ht ranged from 20 to 65%), and acceptable sample stability. The same strategy was successfully applied to another more hydrophilic model compound, MK-0431 (sitagliptin). These results suggest that the previously observed Ht effect and "instability" were in fact due to inconsistent extractability, and optimizing the extraction recovery to greater than 80% was critical to ensure VAMS performance. We recommend adding Ht-independent recovery as part of feasibility assessment to de-risk the long-term extractability-mediated stability bias before implementing VAMS in regulated bioanalysis.
Subject(s)
Blood Specimen Collection/methods , Chemical Fractionation/methods , Dried Blood Spot Testing/methods , Raltegravir Potassium/isolation & purification , Blood Specimen Collection/instrumentation , Chemical Fractionation/instrumentation , Chromatography, High Pressure Liquid , Dried Blood Spot Testing/instrumentation , Drug Stability , Hematocrit , Raltegravir Potassium/blood , Raltegravir Potassium/chemistry , Reference Standards , Sitagliptin Phosphate/blood , Sitagliptin Phosphate/chemistry , Sitagliptin Phosphate/isolation & purification , Tandem Mass SpectrometryABSTRACT
A simple sample treatment procedure and sensitive liquid chromatography-tandem mass spectrometry method were developed for the simultaneous quantification of the concentrations of human immunodeficiency virus-1 integrase strand transfer inhibitors - raltegravir, dolutegravir and elvitegravir - in human plasma and cerebrospinal fluid (CSF). Plasma and CSF samples (20 µL each) were deproteinized with acetonitrile. Raltegravir-d3 was used as the internal standard. Chromatographic separation was achieved on an XBridge C18 column (50 × 2.1 mm i.d., particle size 3.5 µm) using acetonitrile-water (7:3, v/v) containing 0.1% formic acid as the mobile phase at a flow rate of 0.2 mL/min. The run time was 5 min. Calibration curves for all three drugs were linear in the range 5-1500 ng/mL for plasma and 1-200 ng/mL for CSF. The intra- and inter-day precision and accuracy of all three drugs in plasma were coefficient of variation (CV) <12.9% and 100.0 ± 12.2%, respectively, while those in CSF were CV <12.3% and 100.0 ± 7.9%, respectively. Successful validation under the same LC-MS/MS conditions for both plasma and CSF indicates this analytical method is useful for monitoring the levels of these integrase strand transfer inhibitors in the management of treatment of HIV-1 carriers.
Subject(s)
Anti-HIV Agents , Chromatography, High Pressure Liquid/methods , Heterocyclic Compounds, 3-Ring , Quinolones , Raltegravir Potassium , Tandem Mass Spectrometry/methods , Anti-HIV Agents/blood , Anti-HIV Agents/cerebrospinal fluid , Heterocyclic Compounds, 3-Ring/blood , Heterocyclic Compounds, 3-Ring/cerebrospinal fluid , Humans , Linear Models , Oxazines , Piperazines , Pyridones , Quinolones/blood , Quinolones/cerebrospinal fluid , Raltegravir Potassium/blood , Raltegravir Potassium/cerebrospinal fluid , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
OBJECTIVE: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). METHODS: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. RESULTS: Mean saliva-to-plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. CONCLUSIONS: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.â©.
Subject(s)
Anti-HIV Agents/blood , Darunavir/blood , Dideoxynucleosides/blood , HIV Infections/drug therapy , HIV-1/drug effects , Raltegravir Potassium/blood , Saliva/metabolism , Tenofovir/blood , Adult , Aged , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , Chromatography, Liquid , Darunavir/administration & dosage , Darunavir/pharmacokinetics , Dideoxynucleosides/administration & dosage , Dideoxynucleosides/pharmacokinetics , Drug Monitoring/methods , Drug Therapy, Combination , Female , HIV Infections/blood , HIV Infections/diagnosis , HIV Infections/virology , HIV-1/pathogenicity , Humans , Male , Middle Aged , Protein Binding , Raltegravir Potassium/administration & dosage , Raltegravir Potassium/pharmacokinetics , Tandem Mass Spectrometry , Tenofovir/administration & dosage , Tenofovir/pharmacokineticsABSTRACT
Here we describe a case of an HIV-infected young woman with extensive drug-resistant virus, who was successfully switched from a raltegravir-based regimen to a dolutegravir-based intensified antiretroviral regimen a few days before scheduled caesarean section because of the still detectable viral load. The trough concentrations of all antiretroviral drugs before and after delivery are also described. Our case underlines both the difficult management of young women, HIV-infected at young age with very limited treatment options and the great variability in the pregnancy-related physiological changes affecting the pharmacokinetics of antiretrovirals.
Subject(s)
Anti-HIV Agents/pharmacokinetics , Drug Monitoring , Drug Substitution , HIV Infections/drug therapy , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Raltegravir Potassium/pharmacokinetics , Adult , Anti-HIV Agents/blood , Anti-HIV Agents/pharmacology , Biological Availability , Cesarean Section , Drug Administration Schedule , Drug Resistance, Viral/drug effects , Drug Resistance, Viral/genetics , Female , HIV Infections/blood , HIV Infections/virology , HIV-1/drug effects , HIV-1/enzymology , HIV-1/growth & development , Heterocyclic Compounds, 3-Ring/blood , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , Mutation , Oxazines , Piperazines , Pregnancy , Pyridones , Raltegravir Potassium/blood , Raltegravir Potassium/pharmacology , Viral Load/drug effectsABSTRACT
Raltegravir is a human immunodeficiency virus (HIV)-1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice daily (BID). Raltegravir for once daily regimen (QD) at a dose of 1200 mg (2 x 600 mg) is under development and offers a new treatment option for HIV-1 infected treatment-naive subjects. Since raltegravir is eliminated mainly by metabolism via an UDP-glucuronosyltransferase (UGT) 1 A1-mediated glucuronidation pathway, co-administration of UGT1A1 inducers may alter plasma levels of raltegravir. Efavirenz, an UGT1A1 inducer, was used to assess the impact of altered UGT activity on a 1200 mg QD dose of raltegravir. An open label, randomized, 2-period fixed-sequence Phase 1 study was performed in adult healthy male and female subjects (non-childbearing potential) ≥ 19 and ≤55 years of age, with a body mass index (BMI) ≥ 18.5 and ≤32.0 kg/m2 . Subjects (n = 21) received a single oral dose of 1200 mg raltegravir at bedtime on an empty stomach on Day 1 in Period 1. After a washout period of at least 7 days, subjects received oral doses of 600 mg efavirenz QD at bedtime for 14 consecutive days in Period 2. Subjects received a single oral dose of 1200 mg raltegravir co-administered with 600 mg efavirenz on Day 12 of Period 2. Pharmacokinetic (PK) samples were collected for 72 hours following raltegravir dosing and analyzed using a validated bioanalytical method to quantify raltegravir plasma concentrations. PK parameters were estimated using non-compartmental analysis. Administration of single 1200 mg oral doses of raltegravir alone and co-administered with multiple oral doses of efavirenz were generally well tolerated in healthy subjects. Co-administration with efavirenz yielded geometric mean ratios (GMRs) and their associated 90% confidence intervals (90% CIs) for raltegravir AUC0-∞, Cmax , and C24 of 0.86 (0.73, 1.01), 0.91 (0.70, 1.17), and 0.94 (0.76, 1.17), respectively. The results show that efavirenz modestly reduced the exposure of raltegravir. The reduction in raltegravir exposure is not considered clinically meaningful. Copyright © 2016 John Wiley & Sons, Ltd.
Subject(s)
Anti-HIV Agents/blood , Benzoxazines/blood , Glucuronosyltransferase/blood , Raltegravir Potassium/blood , Administration, Oral , Adult , Alkynes , Anti-HIV Agents/administration & dosage , Benzoxazines/administration & dosage , Cyclopropanes , Drug Interactions/physiology , Enzyme Induction/drug effects , Enzyme Induction/physiology , Female , Humans , Male , Middle Aged , Raltegravir Potassium/administration & dosage , Young AdultABSTRACT
Raltegravir is a human immunodeficiency virus (HIV)-1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice-daily (b.i.d.). Raltegravir 1200 mg once-daily (q.d.) (investigational q.d. formulation of 2 × 600 mg tablets; q.d. RAL) was found to be generally well tolerated and non-inferior to the marketed 400 mg b.i.d. dose at 48 weeks in a phase 3 trial. Since raltegravir is eliminated mainly by metabolism via a uridine diphosphate glucuronosyltransferase (UGT) 1A1-mediated glucuronidation pathway, co-administration of UGT1A1 inhibitors may increase the plasma levels of q.d. RAL. To assess this potential, the drug interaction of 1200 mg raltegravir using atazanavir, a known UGT1A1 inhibitor, was studied. An open-label, randomized, 2-period, fixed-sequence phase 1 study was performed in adult healthy male and female (non-childbearing potential) subjects ≥ 19 and ≤ 55 years of age, with a body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 . Subjects (n = 14) received a single oral dose of 1200 mg raltegravir in period 1. After a washout period of at least 7 days, the subjects received oral doses of 400 mg atazanavir q.d. for 9 consecutive days, with a single oral dose of 1200 mg raltegravir co-administered on day 7 of period 2. Serial blood samples were collected for 72 h following raltegravir dosing and analysed using a validated bioanalytical method to quantify raltegravir plasma concentrations. Co-administration with atazanavir yielded GMRs (90% CIs) for raltegravir AUC0-∞ , Cmax and C24 of 1.67 (1.34, 2.10), 1.16 (1.01, 1.33) and 1.26 (1.08, 1.46), respectively. There was no effect of raltegravir on serum total bilirubin. In contrast, atazanavir increased the mean bilirubin by up to 200%, an effect that was preserved in the atazanavir/raltegravir treatment group. Administration of single q.d. RAL alone and co-administered with multiple oral doses of atazanavir were generally well tolerated in healthy subjects. The results show that atazanavir increased the PK exposure of raltegravir; therefore, co-administration of atazanavir with raltegravir q.d. is not recommended. Copyright © 2016 John Wiley & Sons, Ltd.
Subject(s)
Atazanavir Sulfate/blood , HIV Integrase Inhibitors/blood , HIV Protease Inhibitors/blood , Raltegravir Potassium/blood , Administration, Oral , Adult , Atazanavir Sulfate/administration & dosage , Drug Interactions/physiology , Female , HIV Integrase Inhibitors/administration & dosage , HIV Protease Inhibitors/administration & dosage , Humans , Male , Middle Aged , Raltegravir Potassium/administration & dosage , Young AdultABSTRACT
OBJECTIVES: Raltegravir is a human immunodeficiency virus (HIV)-1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice daily (BID). Raltegravir for once-daily regimen (QD) at a dose of 1200 mg is under development. The effect of calcium carbonate and magnesium/aluminium hydroxide antacids on the pharmacokinetics of a 1200 mg dose of raltegravir was assessed in this study. METHODS: An open-label, four-period, four-treatment, fixed-sequence study in 20 HIV-infected patients was performed. Patients needed to be on raltegravir as part of a stable treatment regimen for HIV, and upon entry into the trial received 5 days of 1200 mg raltegravir as pretreatment, before they entered the four-period study: 1200 mg of raltegravir alone (period 1), calcium carbonate antacid as TUMS® Ultra Strength (US) 1000 and 1200 mg raltegravir given concomitantly (Period 2), magnesium/aluminium hydroxide antacid as 20 ml MAALOX® Maximum Strength substitute MS given 12 h after administration of 1200 mg raltegravir (period 3), and calcium carbonate antacid as TUMS® US 1000 given 12 h after administration of 1200 mg raltegravir (period 4). Patients received their dose of 1200 mg QD raltegravir during the intervals between periods to re-establish steady state. AUC0-24 , C24 , Cmax and Tmax were calculated from the individual plasma concentrations of 1200 mg QD raltegravir after administration alone or with a calcium carbonate antacid or with a staggered dose of a calcium carbonate antacid or magnesium/aluminium hydroxide antacid. Adverse events, in addition to laboratory safety tests (haematology, serum chemistry and urinalysis), 12-lead electrocardiograms and vital signs were assessed. KEY FINDINGS: All treatments were well tolerated in the study. Metal-cation antacids variably affected the pharmacokinetics of 1200 mg QD raltegravir. When calcium carbonate antacid was given with 1200 mg raltegravir concomitantly, the geometric mean ratio (GMR) and its associated 90% confidence interval (90% CI) for AUC0-24 , Cmax and C24 h were 0.28 (0.24, 0.32), 0.26 (0.21, 0.32) and 0.52 (0.45, 0.61), respectively. When calcium carbonate antacid and magnesium/aluminium hydroxide were given 12 h after raltegravir 1200 mg QD dosing, the GMR (90% CI) values for AUC0-24 and Cmax were 0.90 (0.80, 1.03), 0.98 (0.81, 1.17), and 0.86 (0.73, 1.03), 0.86 (0.65, 1.15), respectively. However, significant reduction in the trough concentrations of raltegravir was observed: C24 h 0.43 (0.36, 0.51) in the presence of calcium carbonate antacids and 0.42 (0.34, 0.52) in presence of magnesium/aluminium hydroxide, respectively. CONCLUSIONS: Overall, the use of metal-cation antacids with 1200 mg QD raltegravir is not recommended.
Subject(s)
Aluminum Hydroxide/administration & dosage , Antacids/administration & dosage , Calcium Carbonate/administration & dosage , HIV Infections/drug therapy , HIV Integrase Inhibitors/pharmacokinetics , Magnesium Hydroxide/administration & dosage , Magnesium/administration & dosage , Raltegravir Potassium/pharmacokinetics , Administration, Oral , Adult , Aluminum Hydroxide/adverse effects , Antacids/adverse effects , Area Under Curve , Calcium Carbonate/adverse effects , Drug Administration Schedule , Drug Combinations , Drug Interactions , Female , HIV Infections/diagnosis , HIV Infections/virology , HIV Integrase Inhibitors/administration & dosage , HIV Integrase Inhibitors/adverse effects , HIV Integrase Inhibitors/blood , Humans , Magnesium/adverse effects , Magnesium Hydroxide/adverse effects , Male , Metabolic Clearance Rate , Middle Aged , Polypharmacy , Raltegravir Potassium/administration & dosage , Raltegravir Potassium/adverse effects , Raltegravir Potassium/bloodABSTRACT
Raltegravir was recently identified to be a substrate of ATP-binding cassette transporter B1 (ABCB1) and G2 (ABCG2), which are efflux transporters and expressed in the intestines. We analyzed the relations between plasma raltegravir concentrations and single nucleotide polymorphism of ABCB1 and ABCG2 genes. The peak plasma concentration of raltegravir was significantly higher in the patients with ABCB1 4036 AG/GG and ABCG2 421 CA/AA than in other genotype holders (P = 0.0052), though no difference was identified in trough raltegravir concentrations, which may be explained by reduced expression of efflux transporters in intestine by these genetic variants.
Subject(s)
ATP-Binding Cassette Transporters/genetics , HIV Infections/drug therapy , HIV Integrase Inhibitors/blood , Neoplasm Proteins/genetics , Raltegravir Potassium/blood , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 2 , Drug Therapy, Combination , Female , HIV Integrase Inhibitors/therapeutic use , Humans , Japan , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Raltegravir Potassium/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic useSubject(s)
Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , HIV Infections , Hepatitis C, Chronic , Liver Transplantation , Raltegravir Potassium/pharmacokinetics , 2-Naphthylamine , Anilides/therapeutic use , Antiviral Agents/blood , Carbamates/therapeutic use , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , HIV Infections/drug therapy , HIV Infections/metabolism , HIV Infections/surgery , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/metabolism , Hepatitis C, Chronic/surgery , Humans , Lactams, Macrocyclic , Macrocyclic Compounds/therapeutic use , Male , Middle Aged , Proline/analogs & derivatives , Raltegravir Potassium/blood , Raltegravir Potassium/therapeutic use , Ritonavir/therapeutic use , Sulfonamides/therapeutic use , Uracil/analogs & derivatives , Uracil/therapeutic use , ValineABSTRACT
Raltegravir (RAL), an HIV integrase inhibitor, is metabolized mainly by UDP-glucuronosyltransferase 1A1 (UGT1A1). Polymorphisms in UGT1A1 may cause alterations in the pharmacodynamics of RAL, which is taken twice daily with no dietary restrictions. We compared the effect of two polymorphic alleles in this gene, UGT1A1*6 and UGT1A1*28 on plasma RAL concentrations in Japanese HIV-1-infected patients. Of 114 Japanese HIV-1-infected patients who received RAL, the frequencies of UGT1A1*6 and UGT1A1*28 were 18% and 13%, respectively. The percentage of homozygotes for UGT1A1*6 and UGT1A1*28 was 6% and 4%, respectively, the percentage of compound heterozygotes for UGT1A1*6 and UGT1A1*28 was 2%, and that of heterozygotes for UGT1A1*6 and UGT1A1*28 was 22% and 17%, respectively. RAL plasma trough concentrations were compared for each polymorphism. Significantly higher levels of RAL were observed with patients who were homozygous for UGT1A1*6 (median: 1.0 µg/mL) than for the normal allele (median: 0.11 µg/mL; p = 0.021). Multivariate logistic regression analysis showed that the presence of one or two alleles of UGT1A1*6 or two alleles of UGT1A1*28 were independent factors associated with high RAL plasma trough concentrations (≥ 0.17 µg/mL). These results indicated that UGT1A1*6 and UGT1A1*28 are both factors influencing the RAL plasma trough concentrations in Japanese HIV-1-infected patients.
Subject(s)
Glucuronosyltransferase/genetics , HIV Infections/blood , HIV Infections/genetics , Polymorphism, Genetic , Raltegravir Potassium/blood , Raltegravir Potassium/therapeutic use , Glucuronosyltransferase/metabolism , HIV Infections/drug therapy , HIV Integrase Inhibitors/metabolism , HIV Integrase Inhibitors/therapeutic use , Heterozygote , Homozygote , Humans , Japan , Regression AnalysisABSTRACT
A liquid chromatography-tandem mass spectrometry assay for the determination of abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in human plasma and saliva was developed and validated to investigate the applicability of saliva as an appropriate specimen for therapeutic drug monitoring. As internal standards, TFV was chosen for ABC, ABC was chosen for TFV, RAL for DRV, and DRV for RAL. Sample preparation involved protein precipitation with acetonitrile, evaporation of solvent using a centrifugal evaporator, and reconstitution by dissolving the residue in mobile phase. Liquid chromatography was performed on a C18 reverse phase column (1.5 × 50 mm, 5 µm) isocratically at a flow rate of 0.2 mL/min using 5mM formic acid-3% (v/v) acetonitrile as the mobile phase for ABC and TFV and 5mM formic acid-35% (v/v) acetonitrile as the mobile phase for DRV and RAL. The run time was 6 min, and the retention time was approximately 2.0 min for TFV, 2.5 min for RAL, and 4-4.5 min for ABC and DRV. Analytes were detected using tandem mass spectrometry in positive electrospray ionization mode. The precursor/product ion transitions (m/z) were 287.3/191.2 for ABC, 288.5/176.2 for TFV, 548.3/392.3 for DRV, and 445.3/109.5 for RAL, and were monitored on a triple-quadrupole mass spectrometer operated in the multiple reaction monitoring mode. The linearity of the assay was assessed in the range 1-10,000 ng/mL for all four drugs. Within-run and between-run mean accuracy, precision, and the extraction recovery for all drugs were -14.5-18.1%, 1.2-13.1%, and 86.0-111.1%, respectively. The proposed assay is sufficiently sensitive and accurate to quantify these drugs in plasma and saliva, and is suitable for investigating the relationship between drug concentrations in plasma and saliva.
Subject(s)
Darunavir/analysis , Dideoxynucleosides/analysis , Raltegravir Potassium/analysis , Saliva/chemistry , Tenofovir/analysis , Anti-Retroviral Agents/chemistry , Calibration , Chromatography, Liquid , Darunavir/blood , Dideoxynucleosides/blood , Drug Monitoring/methods , Humans , Ions , Limit of Detection , Mass Spectrometry , Raltegravir Potassium/blood , Reproducibility of Results , Solvents/chemistry , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Temperature , Tenofovir/bloodABSTRACT
BACKGROUND: The objective of the study was to assess plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in patients with human immunodeficiency virus-hepatitis C virus (HIV-HCV)-coinfection without liver cirrhosis. METHODS: In this observational, open-label study, adult HIV-infected outpatients treated with tenofovir/emtricitabine plus efavirenz (600 mg daily), darunavir/ritonavir (800/100 mg daily) or raltegravir (400 mg twice daily) for at least 4 weeks were asked to participate. Subjects with liver cirrhosis were excluded. The trough concentration (C trough) of darunavir/ritonavir and raltegravir and the mid-dose concentration (C12h) of efavirenz were assessed at steady state by a validated high-performance liquid chromatography (HPLC)-tandem mass spectrometry method. RESULTS: A total of 96 HIV-positive patients were enrolled into the study. Thirty-four patients were treated with efavirenz, 33 with darunavir/ritonavir and 29 with raltegravir. The geometric mean plasma C trough [coefficient of variation (%)] of darunavir was comparable between HIV+/HCV+ and HIV+/HCV- subjects: 2644 ng/ml (155%) and 2491 ng/ml (139%), respectively (geometric mean ratio (GMR) = 0.81; 95% confidence interval (CI) = 0.79-1.56; p = 0.69). These values were comparable for raltegravir: 108 ng/ml (149%) in the HIV+/HCV+ group and 96 ng/ml (161%) in the HIV+/HCV- group (GMR = 0.84; 95% CI = 0.61-1.44; p = 0.72). On the contrary, the geometric mean plasma C12h of efavirenz was significantly higher among the 15 HIV+/HCV+ patients (1915 ng/ml, 159%) than among the 19 HIV+/HCV- patients (1505 ng/ml, 167%; GMR = 1.41; 95% CI = 1.19-1.71; p = 0.009). CONCLUSIONS: The mean plasma concentration of efavirenz was significantly higher in HCV-positive than in HCV-negative patients without liver cirrhosis, while the mean plasma levels of darunavir/ritonavir and raltegravir were comparable in both groups.
Subject(s)
Anti-HIV Agents/blood , Benzoxazines/blood , Darunavir/blood , HIV Infections/drug therapy , Hepatitis C/complications , Raltegravir Potassium/blood , Ritonavir/blood , Adult , Alkynes , Analysis of Variance , Anti-HIV Agents/therapeutic use , Benzoxazines/pharmacokinetics , Benzoxazines/therapeutic use , Coinfection/drug therapy , Coinfection/epidemiology , Cyclopropanes , Darunavir/pharmacokinetics , Darunavir/therapeutic use , Female , HIV Infections/complications , HIV Infections/epidemiology , Hepatitis C/epidemiology , Humans , Liver Function Tests , Male , Middle Aged , Raltegravir Potassium/pharmacokinetics , Raltegravir Potassium/therapeutic use , Ritonavir/pharmacokinetics , Ritonavir/therapeutic useABSTRACT
Raltegravir is an antiretroviral with potential value for preexposure prophylaxis (PrEP) against HIV, but the intracellular pharmacokinetics in genital tissue have not been described. In this study, healthy, HIV-uninfected nonpregnant women took 400 mg of raltegravir twice daily for 22 days. On day 8, 15, and 22, blood was collected 0, 4, 6, 8, and 12 h and cervical biopsy specimens taken 0, 6, and 12 h after raltegravir dosing. Plasma and intracellular raltegravir concentrations in peripheral blood mononuclear cells (PBMC) and cervical tissue were measured by tandem mass spectrometry. Linear mixed effects models evaluated correlations between different sample types, as well as differences in concentration between phases of the menstrual cycle. Ten women were enrolled: 9 completed all three visits and 1 completed two visits. The age (mean ± standard deviation) of participants was 30 ± 8 years. Trough plasma concentrations of raltegravir 12 h after a directly observed dose were above the HIV 95% inhibitory concentration (IC95) of 33 nM (14.6 ng/ml) in 96% of measurements, compared to 67% of PBMC and 89% of cervical tissue trough values. Across all measurements, only 2% (3/135) of plasma values fell below the IC95, compared to 10% (13/135) for PBMC and 6% (5/81) for cervical tissue. There was no impact of menstrual phase on raltegravir concentrations. In conclusion, cervical tissue raltegravir concentrations were no greater than plasma concentrations, and â¼10% of all cervical tissue trough values were below the IC95, making the current twice-daily formulation of raltegravir impractical for PrEP.
Subject(s)
Anti-Retroviral Agents/pharmacokinetics , Raltegravir Potassium/pharmacokinetics , Adult , Anti-Retroviral Agents/administration & dosage , Anti-Retroviral Agents/blood , Cervix Uteri/metabolism , Cytoplasm/metabolism , Female , Humans , Leukocytes, Mononuclear/metabolism , Raltegravir Potassium/administration & dosage , Raltegravir Potassium/blood , Tandem Mass Spectrometry , Young AdultABSTRACT
Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In this report, we describe a case of sustained and asymptomatic increase of serum CPK concentrations associated with raltegravir, zidovudine, and lamivudine in an HIV-1 experienced patient with intolerance to protease inhibitor, abacavir and pencillin during 32 weeks of continuous drug monitoring.
Un aumento sostenido de las concentraciones de creatina fosfoquinasa sérica (CPK) y las anormalidades musculares ha sido reportado en relación con pacientes que toman raltegravir (RAL). En este reporte, describimos un caso de aumento sostenido y asintomático de concentraciones séricas de CPK asociadas con raltegravir, zidovudina y lamivudina en un paciente experimentado de VIH-1 con intolerancia al inhibidor de la proteasa, al abacavir y la penicilina durante 32 semanas de monitoreo farmacológico continuo.